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R A N D O M I Z E D  C O N T R O L L E D  T R I A L
COMPARISON OF OXYBUTYNIN AND TOLTERODINE IN
TREATMENT OF DETRUSOR OVERACTIVITY ASSOCIATED
WITH UPPER MOTOR NEURON LESIONS, BASED ON
CHANGES IN URODYNAMIC PARAMETERS
BACKGROUND
Upper motor neuron (UMN) injury can result from a large 
number of conditions which are quite common in the 
population. The conditions which lead to UMN lesions 
include cerebrovascular accidents, traumatic brain injury, 
Parkinson’s disease, multiple sclerosis and suprasacral 
spinal cord injury, etc. Detrusor overactivity (DO) is one of 
the deleterious consequences of many upper motor 
neuron lesions. DO is underdiagnosed and commonly 
untreated. The problem is further compounded by 
complications like vesicoureteric reflux, hydronephrosis, 
nephropathy, urinary tract infections, urolithiasis, chronic 
kidney disease and even malignancy.[1] This deteriorates 
the quality of life of the patient not only due to medical 
complications but also because of the ensuing depression 
and social stigmatization thus creating hindrance in early 
achievement of rehabilitation goals. At the same time, the 
complications put an extra burden on the healthcare 
system. This is the reason why treatment of bladder 
dysfunction is an important pillar in the management of 
upper motor neuron lesions. Bladder management in 
UMN lesions focuses on carefully diagnosing the 
underlying bladder disorder and its targeted treatment. 
The treatment of DO can be undertaken on clinical 
grounds but it is beneficial to quantify the defect on 
objective parameters like the urodynamic study because it 
helps in monitoring the response to treatment and in 
gathering data for future follow up. The aim of bladder 
management in DO is to improve the bladder capacity and 
decrease the detrusor contractions in order to enable 
clean intermittent catheterization (CIC) by the patient. 
This can be achieved by various modalities including 
pharmacotherapy as well as surgical options. 
Pharmacotherapy is the most commonly used first line 
treatment because of non-invasiveness, efficacy and ease 
of use. The drug options include anticholinergics/ 
antimuscarinics, tricyclics, intravesical instillation of 
capsaicin or lignocaine and botulinum injections to the 
detrusor muscle. Anti-muscarinic agents are the 
backbone of pharmacological treatment for DO.[2,3] These 
agents are used to abolish detrusor contractions in order 
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to permit voiding by CIC. Antimuscarinics have been 
considered the gold standard of treatment for many 
decades but are well-known for their side effects 
presenting as dry mouth, constipation and tachycardia.  
Oxybutynin is the most commonly used drug in this class 
and can be used orally and/ or intravesically.[4] Tolterodine 
is another commonly used antimuscarinic agent and has 
lesser incidence of side effects than oxybutynin in usual 
doses.[5] Recently, many newer drugs with better 
tolerability have been added to the arsenal against DO.[6] 
In Pakistan, most patients are unable to afford the newer 
agents. The mainstay of treatment for DO remains either 
oxybutynin or tolterodine, out of which oxybutynin is the 
cheaper choice.[7] International studies have proved that 
both these drugs have a comparable efficacy in dealing 
with DO.[8,9,10] No study has been conducted in our 
indigenous population to address this issue so far, using 
objective and measurable outcomes like improvement in 
urodynamic parameters. This issue has been addressed in 
the present study which aims to gather reproducible data 
on the subject.
MATERIALS AND METHODS
It was a single blinded randomized controlled trial carried 
out at Armed Forces Institute of Rehabilitation Medicine, 
Rawalpindi from January 2015 to August 2015. We 
included individuals belonging to both genders fitting in 
the age group of 18-60 years with a diagnosis of DO as a 
result of upper motor neuron lesions. We had chosen the 
above mentioned age limit to lessen the influence of 
confounding factors in geriatric and pediatric population. 
Above 60 years, the females are likely to have stress 
incontinence and males are prone to develop lower 
urinary tract symptoms due to prostatic disease. Likewise, 
the urodynamic parameters in the pediatric population are 
different than adults. Patients having conditions other 
than DO that might have led to urinary incontinence or 
urgency e.g. urinary tract infection, prostatic hypertrophy 
or utero-vaginal prolapse were excluded from the study. 
Smokers and women who were pregnant or breast feeding 
their children were also placed in the exclusion group. 
After approval from the hospital ethics committee, 
prospective candidates for enrollment were evaluated 
thoroughly to meet the inclusion criteria. Patient’s 
informed consent for participation was taken after 
explaining the objectives and benefits of the study. The 
patients who were enrolled underwent baseline 
urodynamic studies using PICO SMART Urodynamics 
System (PICO SMART, Menfis Division, MEDICA S.p.A., 
Bologna, Italy) to quantify maximal detrusor pressure 
(MDP) and maximal cystometric capacity (MCC). MDP is 
the pressure created by bladder wall forces. It is a 
component of intravesical pressure and is calculated by 
subtracting abdominal pressure from intravesical 
pressure. It was measured in cm of H2O. MCC is the 
volume at which the patient feels that he/she can no 
longer delay micturition. It was measured in ml. The 
patients were consecutively divided into two study groups 
i.e. Group A and B. Group A was treated with oral 
tolterodine (Detrusitol, Pfizer Laboratories, Karachi, 
Pakistan) 2 mg twelve hourly [11] and group B received oral 
oxybutynin (Taivor, Raazee Therapeutics, Lahore, 
Pakistan) 3 mg eight hourly.[12] The urodynamic 
parameters assessed at baseline were repeated after four 
weeks. The data were endorsed for each patient in a 
written proforma. The data were analyzed with the help of 
statistical program Statistical Package for Social sciences 
(SPSS) version 19.0 (IBM Corp., Armonk, NY, USA). 
Descriptive statistics were calculated for both qualitative 
and quantitative variables. For qualitative variables like 
gender and primary diagnosis of UMN lesion, frequencies 
and percentages were calculated and for quantitative 
variables like age, MDP and MCC, means and standard 
deviations were calculated. Paired-samples t-test was 
applied to statistically analyze the effect of both 
therapeutic modalities in either study groups. The mean 
reduction in MCC and MDP between two groups were 
compared using independent-samples t-test. A p-value < 
0.05 was considered significant.
RESULTS
A total of 60 patients suffering from UMN pathology 
attributed to various clinical conditions, regardless of age 
and gender, were included in the study. Fifty patients 
(83.3%) were male and ten (16.7%) were female. Mean 
age of the patients was 43.9 ± 15 years with a range of 
13-72 years. The cause of upper motor neuron lesion was 
spinal cord injury in 56.7% (n=34)  of the patients 
followed by cerebrovascular accident (23.3%,n=14), 
Parkinson’s disease (5%,n=3), cerebral palsy (5%, n=3), 
spinal tuberculosis (5%,n=3), acquired brain injury 
(3.3%,n=2) and spinal cord tumors (1.7%, n=1) 
(Figure-1). Mean pre-treatment MCC was 199.1 ± 55.5 
ml, and the mean post-treatment MCC was 295.1 ± 59 
ml. Mean pretreatment MDP was 82.1 ± 10.2 cm of 
H2O, and the mean post-treatment value was 40.8 ± 
10.1 cm of H2O.
 
Figure-1: Figure showing relative percentages of different 
primary etiologies for upper motor neuron lesion in the sample
Twenty-six males and 4 females (n=30) were in group A. 
Rest of the 24 males and 6 females (n=30), were in 
group B. Group A had a mean pre-treatment MCC of 
188.3 ± 48.2 ml, and a mean post-treatment MCC of 
281.5 ± 49.1 ml. (Table-1) The mean pretreatment MDP 
was 83.6 ± 9.5 cm of H2O, and the mean 
post-treatment value was 40.9 ± 10.2 cm of H2O. Group 
B had a mean pre-treatment MCC of 209.8 ± 60.5 ml, 
and mean post-treatment MCC of 308.7 ± 65 ml. The 
mean pretreatment MDP was 80.7 ± 10.6 cm of H2O, 
and the mean post-treatment value was 40.7 ± 10.1 cm 
of H2O.(Table-1)
Each drug significantly reduced MCC and MDP in its group 
(p< 0.001, p< 0.001, p< 0.001 and p< 0.001 
respectively). The mean reduction in MCC produced by 
tolterodine (93.2 ± 18.6) was less than that produced by 
oxybutynin (98.9 ± 26.7) but did not satisfy the statistical 
tests for significance (p=0.179). Similarly, the mean 
reduction in MDP produced by tolterodine (42.7 ± 3.9) 
was more than that produced by oxybutynin (40 ± 10.6) 
but could not reach a statistically significant value (p= 
0.068).
DISCUSSION
DO is commonly seen in patients with UMN lesions as 
evidenced by various community and hospital based 
surveys. The complications relating to this disorder are 
also quite frequent in this population which can be 
averted to some extent by the use of appropriate 
modalities. For these patients the care of the bladder is an 
essential component of any rehabilitation program. In 
practice, balancing between efficacy and side effects is a 
challenge. Moreover, cost effectiveness is a major 
determinant in choosing the appropriate drugs especially 
in poor countries. A lot of studies have been conducted to 
determine the safety and efficacy of antimuscarinic 
agents that are the cornerstone of treatment in patients 
with both neurogenic and non-neurogenic DO. We also 
tried to find out the difference in efficacy of commonly 
available antimuscarinic agents available in Pakistan while 
targeting Pakistani population. We found that, though 
both tolterodine and oxybutynin were effective in reducing 
MDP and MCC, there was no significant difference in the 
magnitude of effect produced by both drugs. Madhuvrata 
P et al. embarked upon a study to compare the two drugs 
in question in our study. They concentrated on bladder 
leakage episodes in 24 hours and patients’ perception of 
improvement in quality of life. Their results were similar to 
ours in that both the drugs caused significant but 
comparable improvements in subjective parameters. [13] 
In a double blind, multicenter study carried out to 
compare relative effectiveness of tolterodine (4 mg daily), 
transdermal oxybutynin and placebo [14], no significant 
differences were seen in the outcome parameters 
between the two drugs. However, both were significantly 
more effective than placebo in reducing incontinence 
episodes (75% vs 50%) both P < 0.05 vs placebo. In the 
Overactive Bladder: Performance of Extended Release 
Agents (OPERA) trial, a comparison was made between 
extended release oxybutynin (OXY-ER, 10 mg) and 
tolterodine(TOL-ER, 4 mg). With both these drugs, 
comparable results were obtained regarding control of 
incontinence. However oxybutynin was found to had a 
greater impact on the total micturition frequency per week 
(28.4 vs 25.2; P = 0.003) as well as overall dry rate 
(23% vs 16.8%; P = 0.03).[15] Many studies have 
established a superiority of tolterodine over oxybutynin in 
side effects’ profile. This has led to more compliance with 
tolterodine therapy and fewer dropouts. The side effect 
profile was found to be much better especially with 
dryness of mouth and cognitive impairment. This is 
because tolterodine has been documented to have 8-fold 
less affinity to the muscarinic receptors at the parotid 
gland in radioligand binding.[16, 17, 18] We under took this 
study because of the high burden of this disorder in the 
outdoor and as well as the indoor in our Institute. We 
searched but did not find a single indigenous study on this 
topic using urodynamic parameters as the gauge to 
determine efficacy. Our study was carried out to try to 
address this issue. We, the physicians in the third world, 
more than our counterparts in the developed world, have 
to balance the efficacy of a drug against its cost. 
Oxybutynin is a relatively cheaper drug and therefore is 
more easily available to our patients. Based on the 
volume of literature in favor of comparable effectiveness 
of oxybutynin and tolterodine, we chose the null 
hypothesis to be the expected outcome on urodynamic 
parameters. As hypothesized, our results revealed no 
significant difference in the relative effectiveness of these 
two drugs. Therefore our study validates the results of 
previous studies as mentioned above. This has helped us 
to be more confident in prescribing this drug without 
feeling the guilt of withholding a potentially better drug 
because of financial constraints. The study had a 
shortcoming. A long term follow up was required to 
determine the relative frequency of long term treatment 
failures and dropouts amongst the two groups which could 
not be carried out properly because of time limitation.
CONCLUSIONS
Both oxybutynin and tolterodine showed similar efficacy in 
the treatment of DO based on measurable urodynamic 
outcomes. The improvements in the urodynamic 
parameters were significant with both these drugs, so 
their regular use in appropriate patients is justified. Our 
study was the first of its kind in Pakistan. As mentioned 
earlier, the database available on DO is not of a very high 
quality, therefore there is a need to continue research on 
this subject to further elucidate the differences in 
response to treatment, if any, amongst the various causes 
of neurogenic bladder.
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INTRODUCTION
Epilepsy is a chronic condition in which non-compliance is 
considered to be a significant problem faced during clinical 
treatment. Poor compliance to treatment is one of many 
reasons for pharmacological treatment failure and seizure 
recurrence. Despite all the best intention and efforts on 
the part of the healthcare professionals, those outcomes 
might not be achievable if the patients are non-compliant. 
(1) The behavior of compliance depends on specific clinical 
situation, nature of the illness, and treatment program. 
The effect of recurrent epileptic seizure attacks on the 
patient is far reaching. Poor compliance may lead to status 
epilepticus, as well as unexpected, sudden death. (2) 
Recurrent convulsions can reduce the likelihood of 
eventually curing the disorder. With appropriate treatment 
and lifestyle changes, the majority of patients diagnosed 
with epilepsy will become seizure-free. Compliant 
behaviour can be defined as taking anti-epileptic drugs 
(AEDs) on time and without fail, not manipulating dosages, 
and following the doctor’s advice regarding daily activities. 
(2) Non-compliance is a significant problem in epilepsy 
management. As many as 30 to 50% of persons with 
epilepsy are non-compliant to the extent of interfering with 
their optimal treatment. (2) The effect of non-compliance is 
enormous and may lead to an increase in the number of 
seizures, medical costs and injury to themselves and 
others.(2) The frequency of non-compliance was 19% in the 
outpatient group as reported in one study. (3) Reasons for 
non-compliance are complex and multilayered. Patients 
can accidentally fail to adhere through forgetfulness, 
misunderstanding, or uncertainty about clinician’s 
recommendations, or intentionally due to their own 
expectations of treatment, side-effects, and lifestyle 
choice. (3) In India, a study relating to doctor-patient 
communication and compliance stated that compliance 
improved when patients were satisfied with the 
consultation process and were asked to recall the 
information. Multiple visits to the doctor enhanced 
communication, and thus compliant behaviour. (4) Most of 
studies have attempted either to identify predictors or to 
measure the incidence of non-compliance but there is not 
a validated scale for measuring epilepsy patient 
non-compliance to antiepileptic drugs. This is especially 
true for developing countries including Pakistan. The lack 
of these measurements provides difficulties to assess the 
impact of specific factors in compliance to treatment. 
Services Hospital is the regional hospital in the central 
Punjab and serves a huge population of the country. There 
is scarcity of published data reporting the prevalence of 
epileptic patients with noncompliance of antiepileptic 
drugs. In the present study, we have aimed to determine 
the prevalence of compliance and non-compliance of 
antiepileptic drugs in epileptic patients. 
MATERIALS AND METHODS
The present study was conducted in OPD (Outpatient 
Department) at Services Institute of Medical Sciences and 
Services Hospital, Lahore, Pakistan. This 6-month 
descriptive study was carried out in 2012 and included a 
total of 225 patients who were admitted with the primary 
diagnosis of Epilepsy. Male and female patients aged 
between 10 to 70 years, who had been diagnosed with 
epilepsy at least one year previously, were included. 
Patients having other co-morbidities were excludded from 
this study. The data-collection tools were a questionnaire 
and a structured interview. Patients who were not able to 
respond to an interview were also excluded. For each 
patient detail history was taken including demographic 
information (age, sex, address) and questionnaire was 
asked after taking informed consent by researcher herself. 
All patients were observed for anti-epilepsy drug 
compliance and non-compliance. Patients included in 
study, were treated free of cost. Participants gave written 
informed consent after the purpose of the study had been 
explained to them. The ethics committee of the hospital 
approved the study. 
Statistical Analyses
The descriptive statistical analysis included examinations 
of means, standard deviations, frequencies, ranges, and 
percentages. The statistical packages SPSS (Version 20) 
and MS Excel (MS Office 2010) were used. 
RESULTS
A total of 225 patients fulfilling the inclusion criteria were 
enrolled to measure the frequency of noncompliance of 
antiepileptic drugs in epileptic patients. Age distribution of 
the patients was done which showed that 29.78% 
(n=67) were between 10-30 years, 36% (n=81) 
between 41-55 years and 34.22% (n=77) were between 
56-70 years of age. Average age of the patients was 
46.87+5.23 years (Table 1). 
Table 1. Age distribution of patients included in the study.
Mean and SD: 46.87+5.23 (n= 225)
Gender distribution of the patients showed that 59.6% 
(n=134) were males and 40.4% (n=91) were females 
(Table 2). 
Table 2. Gender distribution of all patients included in this 
study.
Results regarding the frequency of epileptic patients with 
compliance and non-compliance of antiepileptic drugs 
have been shown in Figure 1. Figure shows that out of 
225 patients, 172 patients (76.4%) had compliance of 
antiepileptic drugs. Whereas 53 patients (23.6%) showed 
non-compliance to antiepileptic drugs (Figure 1).
 
Figure 1. Frequency of compliance and non-compliance 
of antiepileptic drugs among epileptic patients.
We also identified the gender distribution of epileptic 
patients with non-compliance of antiepileptic drugs. The 
results have been shown in Table 3 which shows that out 
of 53 cases of non-compliance, 33 cases (62.3%) were 
male and 20 cases (37.7%) were females (Table 3). This 
finding showed that incidence of non-compliance was 
more frequent in males as compared to females.
Table 3. Stratification for noncompliance of antiepileptic 




The sole treatment available for the majority of patients 
with epilepsy is antiepileptic drug (AED) therapy. Research 
has shown that missing or altering antiepileptic drug 
dosages can have adverse reactions, that is, increase the 
chance of seizure recurrence. For instance, Mattson et al. 
reported that over one quarter of seizures occurred at or 
before reports of inadequate medication levels. Failure to 
follow prescribed drug regimens is known to be fairly 
widespread amongst patients with epilepsy: research has 
shown that between 25 and 75% fail to adhere, in 
particular very young or very old patients, and teenagers. 
Given that failing to comply may increase the likelihood of 
hospital admission, there could be a potential savings if 
compliance could be improved. We planned this study to 
determine the most prevalent factors in Pakistan because 
demographic, psychosocial, economic factors, literacy 
rate is different. Non-compliance of antiepileptic drugs in 
epileptic patients leads to recurrent seizures, thus mental 
regression occurs (2); by knowing the frequency of 
non-compliance, we can adopt some strategies to 
over-come this problem to improve levels of compliance 
thereby reducing the risk of unnecessary seizures. In this 
study, frequency of non-compliance of antiepileptic drugs 
in epileptic patients was revealed in 23.56% while 
76.44% had no complaint of non-compliance. The 
findings of the present study regarding frequency of 
non-compliance are in agreement with Hauser et al. (5) 
WHO reported that 19% of the patients had 
non-compliance in the outpatient group.(5) The evidence 
indicates that non-compliance is still common in 
healthcare and no substantial change occurred despite 
the large number of studies attempting to address and 
highlight the problem. In addition, too few studies are 
being done systematically to quantify the impact of 
non-compliance on health and financial outcomes. The 
magnitude of the impact of non-compliance needs to be 
studied in future compliance research due to the potential 
tremendous implication of poor compliance on clinical 
and economic outcomes.
CONCLUSION
We concluded that the frequency of noncompliance of 
antiepileptic drugs among epileptic patients is higher. This 
condition is worsening for males since they showed a 
greater percentage of non-compliance as compared to 
females. This situation needs special attention of the 
physicians while managing epileptic patients.
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BACKGROUND
Upper motor neuron (UMN) injury can result from a large 
number of conditions which are quite common in the 
population. The conditions which lead to UMN lesions 
include cerebrovascular accidents, traumatic brain injury, 
Parkinson’s disease, multiple sclerosis and suprasacral 
spinal cord injury, etc. Detrusor overactivity (DO) is one of 
the deleterious consequences of many upper motor 
neuron lesions. DO is underdiagnosed and commonly 
untreated. The problem is further compounded by 
complications like vesicoureteric reflux, hydronephrosis, 
nephropathy, urinary tract infections, urolithiasis, chronic 
kidney disease and even malignancy.[1] This deteriorates 
the quality of life of the patient not only due to medical 
complications but also because of the ensuing depression 
and social stigmatization thus creating hindrance in early 
achievement of rehabilitation goals. At the same time, the 
complications put an extra burden on the healthcare 
system. This is the reason why treatment of bladder 
dysfunction is an important pillar in the management of 
upper motor neuron lesions. Bladder management in 
UMN lesions focuses on carefully diagnosing the 
underlying bladder disorder and its targeted treatment. 
The treatment of DO can be undertaken on clinical 
grounds but it is beneficial to quantify the defect on 
objective parameters like the urodynamic study because it 
helps in monitoring the response to treatment and in 
gathering data for future follow up. The aim of bladder 
management in DO is to improve the bladder capacity and 
decrease the detrusor contractions in order to enable 
clean intermittent catheterization (CIC) by the patient. 
This can be achieved by various modalities including 
pharmacotherapy as well as surgical options. 
Pharmacotherapy is the most commonly used first line 
treatment because of non-invasiveness, efficacy and ease 
of use. The drug options include anticholinergics/ 
antimuscarinics, tricyclics, intravesical instillation of 
capsaicin or lignocaine and botulinum injections to the 
detrusor muscle. Anti-muscarinic agents are the 
backbone of pharmacological treatment for DO.[2,3] These 
agents are used to abolish detrusor contractions in order 
to permit voiding by CIC. Antimuscarinics have been 
considered the gold standard of treatment for many 
decades but are well-known for their side effects 
presenting as dry mouth, constipation and tachycardia.  
Oxybutynin is the most commonly used drug in this class 
and can be used orally and/ or intravesically.[4] Tolterodine 
is another commonly used antimuscarinic agent and has 
lesser incidence of side effects than oxybutynin in usual 
doses.[5] Recently, many newer drugs with better 
tolerability have been added to the arsenal against DO.[6] 
In Pakistan, most patients are unable to afford the newer 
agents. The mainstay of treatment for DO remains either 
oxybutynin or tolterodine, out of which oxybutynin is the 
cheaper choice.[7] International studies have proved that 
both these drugs have a comparable efficacy in dealing 
with DO.[8,9,10] No study has been conducted in our 
indigenous population to address this issue so far, using 
objective and measurable outcomes like improvement in 
urodynamic parameters. This issue has been addressed in 
the present study which aims to gather reproducible data 
on the subject.
MATERIALS AND METHODS
It was a single blinded randomized controlled trial carried 
out at Armed Forces Institute of Rehabilitation Medicine, 
Rawalpindi from January 2015 to August 2015. We 
included individuals belonging to both genders fitting in 
the age group of 18-60 years with a diagnosis of DO as a 
result of upper motor neuron lesions. We had chosen the 
above mentioned age limit to lessen the influence of 
confounding factors in geriatric and pediatric population. 
Above 60 years, the females are likely to have stress 
incontinence and males are prone to develop lower 
urinary tract symptoms due to prostatic disease. Likewise, 
the urodynamic parameters in the pediatric population are 
different than adults. Patients having conditions other 
than DO that might have led to urinary incontinence or 
urgency e.g. urinary tract infection, prostatic hypertrophy 
or utero-vaginal prolapse were excluded from the study. 
Smokers and women who were pregnant or breast feeding 
their children were also placed in the exclusion group. 
After approval from the hospital ethics committee, 
prospective candidates for enrollment were evaluated 
thoroughly to meet the inclusion criteria. Patient’s 
informed consent for participation was taken after 
explaining the objectives and benefits of the study. The 
patients who were enrolled underwent baseline 
urodynamic studies using PICO SMART Urodynamics 
System (PICO SMART, Menfis Division, MEDICA S.p.A., 
Bologna, Italy) to quantify maximal detrusor pressure 
(MDP) and maximal cystometric capacity (MCC). MDP is 
the pressure created by bladder wall forces. It is a 
component of intravesical pressure and is calculated by 
subtracting abdominal pressure from intravesical 
pressure. It was measured in cm of H2O. MCC is the 
volume at which the patient feels that he/she can no 
longer delay micturition. It was measured in ml. The 
patients were consecutively divided into two study groups 
i.e. Group A and B. Group A was treated with oral 
tolterodine (Detrusitol, Pfizer Laboratories, Karachi, 
Pakistan) 2 mg twelve hourly [11] and group B received oral 
oxybutynin (Taivor, Raazee Therapeutics, Lahore, 
Pakistan) 3 mg eight hourly.[12] The urodynamic 
parameters assessed at baseline were repeated after four 
weeks. The data were endorsed for each patient in a 
written proforma. The data were analyzed with the help of 
statistical program Statistical Package for Social sciences 
(SPSS) version 19.0 (IBM Corp., Armonk, NY, USA). 
Descriptive statistics were calculated for both qualitative 
and quantitative variables. For qualitative variables like 
gender and primary diagnosis of UMN lesion, frequencies 
and percentages were calculated and for quantitative 
variables like age, MDP and MCC, means and standard 
deviations were calculated. Paired-samples t-test was 
applied to statistically analyze the effect of both 
therapeutic modalities in either study groups. The mean 
reduction in MCC and MDP between two groups were 
compared using independent-samples t-test. A p-value < 
0.05 was considered significant.
RESULTS
A total of 60 patients suffering from UMN pathology 
attributed to various clinical conditions, regardless of age 
and gender, were included in the study. Fifty patients 
(83.3%) were male and ten (16.7%) were female. Mean 
age of the patients was 43.9 ± 15 years with a range of 
13-72 years. The cause of upper motor neuron lesion was 
spinal cord injury in 56.7% (n=34)  of the patients 
followed by cerebrovascular accident (23.3%,n=14), 
Parkinson’s disease (5%,n=3), cerebral palsy (5%, n=3), 
spinal tuberculosis (5%,n=3), acquired brain injury 
(3.3%,n=2) and spinal cord tumors (1.7%, n=1) 
(Figure-1). Mean pre-treatment MCC was 199.1 ± 55.5 
ml, and the mean post-treatment MCC was 295.1 ± 59 
ml. Mean pretreatment MDP was 82.1 ± 10.2 cm of 
H2O, and the mean post-treatment value was 40.8 ± 
10.1 cm of H2O.
 
Figure-1: Figure showing relative percentages of different 
primary etiologies for upper motor neuron lesion in the sample
Twenty-six males and 4 females (n=30) were in group A. 
Rest of the 24 males and 6 females (n=30), were in 
group B. Group A had a mean pre-treatment MCC of 
188.3 ± 48.2 ml, and a mean post-treatment MCC of 
281.5 ± 49.1 ml. (Table-1) The mean pretreatment MDP 
was 83.6 ± 9.5 cm of H2O, and the mean 
post-treatment value was 40.9 ± 10.2 cm of H2O. Group 
B had a mean pre-treatment MCC of 209.8 ± 60.5 ml, 
and mean post-treatment MCC of 308.7 ± 65 ml. The 
mean pretreatment MDP was 80.7 ± 10.6 cm of H2O, 
and the mean post-treatment value was 40.7 ± 10.1 cm 
of H2O.(Table-1)
Each drug significantly reduced MCC and MDP in its group 
(p< 0.001, p< 0.001, p< 0.001 and p< 0.001 
respectively). The mean reduction in MCC produced by 
tolterodine (93.2 ± 18.6) was less than that produced by 
oxybutynin (98.9 ± 26.7) but did not satisfy the statistical 
tests for significance (p=0.179). Similarly, the mean 
reduction in MDP produced by tolterodine (42.7 ± 3.9) 
was more than that produced by oxybutynin (40 ± 10.6) 
but could not reach a statistically significant value (p= 
0.068).
DISCUSSION
DO is commonly seen in patients with UMN lesions as 
evidenced by various community and hospital based 
surveys. The complications relating to this disorder are 
also quite frequent in this population which can be 
averted to some extent by the use of appropriate 
modalities. For these patients the care of the bladder is an 
essential component of any rehabilitation program. In 
practice, balancing between efficacy and side effects is a 
challenge. Moreover, cost effectiveness is a major 
determinant in choosing the appropriate drugs especially 
in poor countries. A lot of studies have been conducted to 
determine the safety and efficacy of antimuscarinic 
agents that are the cornerstone of treatment in patients 
with both neurogenic and non-neurogenic DO. We also 
tried to find out the difference in efficacy of commonly 
available antimuscarinic agents available in Pakistan while 
targeting Pakistani population. We found that, though 
both tolterodine and oxybutynin were effective in reducing 
MDP and MCC, there was no significant difference in the 
magnitude of effect produced by both drugs. Madhuvrata 
P et al. embarked upon a study to compare the two drugs 
in question in our study. They concentrated on bladder 
leakage episodes in 24 hours and patients’ perception of 
improvement in quality of life. Their results were similar to 
ours in that both the drugs caused significant but 
comparable improvements in subjective parameters. [13] 
In a double blind, multicenter study carried out to 
compare relative effectiveness of tolterodine (4 mg daily), 
transdermal oxybutynin and placebo [14], no significant 
differences were seen in the outcome parameters 
between the two drugs. However, both were significantly 
more effective than placebo in reducing incontinence 
episodes (75% vs 50%) both P < 0.05 vs placebo. In the 
Overactive Bladder: Performance of Extended Release 
Agents (OPERA) trial, a comparison was made between 
extended release oxybutynin (OXY-ER, 10 mg) and 
tolterodine(TOL-ER, 4 mg). With both these drugs, 
comparable results were obtained regarding control of 
incontinence. However oxybutynin was found to had a 
greater impact on the total micturition frequency per week 
(28.4 vs 25.2; P = 0.003) as well as overall dry rate 
(23% vs 16.8%; P = 0.03).[15] Many studies have 
established a superiority of tolterodine over oxybutynin in 
side effects’ profile. This has led to more compliance with 
tolterodine therapy and fewer dropouts. The side effect 
profile was found to be much better especially with 
dryness of mouth and cognitive impairment. This is 
because tolterodine has been documented to have 8-fold 
less affinity to the muscarinic receptors at the parotid 
gland in radioligand binding.[16, 17, 18] We under took this 
study because of the high burden of this disorder in the 
outdoor and as well as the indoor in our Institute. We 
searched but did not find a single indigenous study on this 
topic using urodynamic parameters as the gauge to 
determine efficacy. Our study was carried out to try to 
address this issue. We, the physicians in the third world, 
more than our counterparts in the developed world, have 
to balance the efficacy of a drug against its cost. 
Oxybutynin is a relatively cheaper drug and therefore is 
more easily available to our patients. Based on the 
volume of literature in favor of comparable effectiveness 
of oxybutynin and tolterodine, we chose the null 
hypothesis to be the expected outcome on urodynamic 
parameters. As hypothesized, our results revealed no 
significant difference in the relative effectiveness of these 
two drugs. Therefore our study validates the results of 
previous studies as mentioned above. This has helped us 
to be more confident in prescribing this drug without 
feeling the guilt of withholding a potentially better drug 
because of financial constraints. The study had a 
shortcoming. A long term follow up was required to 
determine the relative frequency of long term treatment 
failures and dropouts amongst the two groups which could 
not be carried out properly because of time limitation.
CONCLUSIONS
Both oxybutynin and tolterodine showed similar efficacy in 
the treatment of DO based on measurable urodynamic 
outcomes. The improvements in the urodynamic 
parameters were significant with both these drugs, so 
their regular use in appropriate patients is justified. Our 
study was the first of its kind in Pakistan. As mentioned 
earlier, the database available on DO is not of a very high 
quality, therefore there is a need to continue research on 
this subject to further elucidate the differences in 
response to treatment, if any, amongst the various causes 
of neurogenic bladder.
REFERENCES
1. Verpoorten C, Buyse GM. The neurogenic bladder: 
 medical treatment. Pediatr Nephrol 2008;23(5): 
 717-25.
2. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its 
 pharmacodynamic and pharmacokinetic properties, 
 and its therapeutic use in detrusor instability. Drugs 
 Aging 1995;6(3):243-62.
3. Ouslander JG, Blaustein J, Connor A, Orzeck S, Yong 
 CL. Pharmacokinetics and clinical effects of oxybutynin
 in geriatric patients. J Urol 1988;140(1):47–50.
4. Evans RJ. Intravesical therapy for overactive bladder.
 Curr Urol Rep 2005;6(6):429-33. 
5. Abrams P, Freeman R, Anderström C, Mattiasson A. 
 Tolterodine, a new antimuscarinic agent: as effective 
 but better tolerated than oxybutynin in patients with 
 an overactive bladder. Br J Urol 1998;81(6):801-10. 
6. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of 
 darifenacin, a muscarinic M3 selective receptor
 antagonist (M3 SRA), compared with oxybutynin in
  the treatment of patients with overactive bladder. 
 World J Urol 2005;23(4):248-52. 
7. Hughes DA, Dubois D. Cost-effectiveness analysis of 
 extended-release formulations of oxybutynin and 
 tolterodine for the management of urge incontinence. 
 Pharmacoeconomics 2004;22(16):1047-59. 
8. Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan 
 E, Hoel G. Efficacy and safety of transdermal and oral 
 oxybutynin in children with neurogenic detrusor 
 overactivity. J Urol 2009;182(4):1548-54. 
9. Chancellor MB, Anderson RU, Boone TB. Pharma- 
 cotherapy for neurogenic detrusor overactivity. Am J
 Phys Med Rehabil 2006;85(6):536-45. 
10. Christoph F, Moschkowitsch A, Kempkensteffen C,
 Schostak M, Miller K, Schrader M. Long-term efficacy 
 of tolterodine and patient compliance in pediatric 
 patients with neurogenic detrusor overactivity. Urol Int 
 2007;79(1):55-9.
11. Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers 
 OI. Efficacy and safety of tolterodine in people with 
 neurogenic detrusor overactivity. J Spinal Cord Med
 2004;27(3):214-8.
12. Diokno A, Ingber M. Oxybutynin in detrusor overactivity.
 Urol Clin North Am 2006;33(4):439-45, vii.
13. Madhuvrata P, Cody JD, Ellis G, Herbison GP, 
 Hay-Smith EJ. Which anticholinergic drug for 
 overactive bladder symptoms in adults. Cochrane
 Database Syst Rev 2012;1:CD005429.
14. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, 
 Davila GW, Sanders SW. Transdermal Oxybutynin 
 Study Group. Comparative efficacy and safety of 
 transdermal oxybutynin and oral tolterodine versus
 placebo in previously treated  patients with urge and 
 mixed urinary incontinence. Urology 2003; 62(2):
 237-42.
15. Kennelly MJ. A comparative review of oxybutynin 
 chloride formulations: pharmacokinetics and
 therapeutic efficacy in overactive bladder. Rev Urol 
 2010;12(1):12-9.
16. Brynne N, Stahl MM, Hallén B, Edlund PO, Palmér L, 
 Höglund P, et al. Pharmacokinetics and pharma- 
 codynamics of tolterodine in man: a new drug for the 
 treatment of urinary bladder overactivity. Int J 
 Clin Pharmacol Ther 1997;35(7):287-95.
17. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, 
 Sparf B. Tolterodine--a new bladder-selective 
 antimuscarinic agent. Eur J Pharmacol 1997; 
 327(2-3):195-207.
18. Suguino RS, Martins G, Campos BCV, Bessa RF, Polli 
 DA, Funez MI, et al. Oxybutynin and tolterodine for 
 treatment of neurogenic detrusor overactivity: a 
 pharmacoeconomic evaluation in the Brazilian 
 context. Brazilian Journal of Pharmaceutical Sciences 
 2012;48(2):227-36.
P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S 02 V O L .  1 0  ( 4 )  O C T  -  D E C  2 0 1 5
INTRODUCTION
Epilepsy is a chronic condition in which non-compliance is 
considered to be a significant problem faced during clinical 
treatment. Poor compliance to treatment is one of many 
reasons for pharmacological treatment failure and seizure 
recurrence. Despite all the best intention and efforts on 
the part of the healthcare professionals, those outcomes 
might not be achievable if the patients are non-compliant. 
(1) The behavior of compliance depends on specific clinical 
situation, nature of the illness, and treatment program. 
The effect of recurrent epileptic seizure attacks on the 
patient is far reaching. Poor compliance may lead to status 
epilepticus, as well as unexpected, sudden death. (2) 
Recurrent convulsions can reduce the likelihood of 
eventually curing the disorder. With appropriate treatment 
and lifestyle changes, the majority of patients diagnosed 
with epilepsy will become seizure-free. Compliant 
behaviour can be defined as taking anti-epileptic drugs 
(AEDs) on time and without fail, not manipulating dosages, 
and following the doctor’s advice regarding daily activities. 
(2) Non-compliance is a significant problem in epilepsy 
management. As many as 30 to 50% of persons with 
epilepsy are non-compliant to the extent of interfering with 
their optimal treatment. (2) The effect of non-compliance is 
enormous and may lead to an increase in the number of 
seizures, medical costs and injury to themselves and 
others.(2) The frequency of non-compliance was 19% in the 
outpatient group as reported in one study. (3) Reasons for 
non-compliance are complex and multilayered. Patients 
can accidentally fail to adhere through forgetfulness, 
misunderstanding, or uncertainty about clinician’s 
recommendations, or intentionally due to their own 
expectations of treatment, side-effects, and lifestyle 
choice. (3) In India, a study relating to doctor-patient 
communication and compliance stated that compliance 
improved when patients were satisfied with the 
consultation process and were asked to recall the 
information. Multiple visits to the doctor enhanced 
communication, and thus compliant behaviour. (4) Most of 
studies have attempted either to identify predictors or to 
measure the incidence of non-compliance but there is not 
a validated scale for measuring epilepsy patient 
non-compliance to antiepileptic drugs. This is especially 
true for developing countries including Pakistan. The lack 
of these measurements provides difficulties to assess the 
impact of specific factors in compliance to treatment. 
Services Hospital is the regional hospital in the central 
Punjab and serves a huge population of the country. There 
is scarcity of published data reporting the prevalence of 
epileptic patients with noncompliance of antiepileptic 
drugs. In the present study, we have aimed to determine 
the prevalence of compliance and non-compliance of 
antiepileptic drugs in epileptic patients. 
MATERIALS AND METHODS
The present study was conducted in OPD (Outpatient 
Department) at Services Institute of Medical Sciences and 
Services Hospital, Lahore, Pakistan. This 6-month 
descriptive study was carried out in 2012 and included a 
total of 225 patients who were admitted with the primary 
diagnosis of Epilepsy. Male and female patients aged 
between 10 to 70 years, who had been diagnosed with 
epilepsy at least one year previously, were included. 
Patients having other co-morbidities were excludded from 
this study. The data-collection tools were a questionnaire 
and a structured interview. Patients who were not able to 
respond to an interview were also excluded. For each 
patient detail history was taken including demographic 
information (age, sex, address) and questionnaire was 
asked after taking informed consent by researcher herself. 
All patients were observed for anti-epilepsy drug 
compliance and non-compliance. Patients included in 
study, were treated free of cost. Participants gave written 
informed consent after the purpose of the study had been 
explained to them. The ethics committee of the hospital 
approved the study. 
Statistical Analyses
The descriptive statistical analysis included examinations 
of means, standard deviations, frequencies, ranges, and 
percentages. The statistical packages SPSS (Version 20) 
and MS Excel (MS Office 2010) were used. 
RESULTS
A total of 225 patients fulfilling the inclusion criteria were 
enrolled to measure the frequency of noncompliance of 
antiepileptic drugs in epileptic patients. Age distribution of 
the patients was done which showed that 29.78% 
(n=67) were between 10-30 years, 36% (n=81) 
between 41-55 years and 34.22% (n=77) were between 
56-70 years of age. Average age of the patients was 
46.87+5.23 years (Table 1). 
Table 1. Age distribution of patients included in the study.
Mean and SD: 46.87+5.23 (n= 225)
Gender distribution of the patients showed that 59.6% 
(n=134) were males and 40.4% (n=91) were females 
(Table 2). 
Table 2. Gender distribution of all patients included in this 
study.
Results regarding the frequency of epileptic patients with 
compliance and non-compliance of antiepileptic drugs 
have been shown in Figure 1. Figure shows that out of 
225 patients, 172 patients (76.4%) had compliance of 
antiepileptic drugs. Whereas 53 patients (23.6%) showed 
non-compliance to antiepileptic drugs (Figure 1).
 
Figure 1. Frequency of compliance and non-compliance 
of antiepileptic drugs among epileptic patients.
We also identified the gender distribution of epileptic 
patients with non-compliance of antiepileptic drugs. The 
results have been shown in Table 3 which shows that out 
of 53 cases of non-compliance, 33 cases (62.3%) were 
male and 20 cases (37.7%) were females (Table 3). This 
finding showed that incidence of non-compliance was 
more frequent in males as compared to females.
Table 3. Stratification for noncompliance of antiepileptic 




The sole treatment available for the majority of patients 
with epilepsy is antiepileptic drug (AED) therapy. Research 
has shown that missing or altering antiepileptic drug 
dosages can have adverse reactions, that is, increase the 
chance of seizure recurrence. For instance, Mattson et al. 
reported that over one quarter of seizures occurred at or 
before reports of inadequate medication levels. Failure to 
follow prescribed drug regimens is known to be fairly 
widespread amongst patients with epilepsy: research has 
shown that between 25 and 75% fail to adhere, in 
particular very young or very old patients, and teenagers. 
Given that failing to comply may increase the likelihood of 
hospital admission, there could be a potential savings if 
compliance could be improved. We planned this study to 
determine the most prevalent factors in Pakistan because 
demographic, psychosocial, economic factors, literacy 
rate is different. Non-compliance of antiepileptic drugs in 
epileptic patients leads to recurrent seizures, thus mental 
regression occurs (2); by knowing the frequency of 
non-compliance, we can adopt some strategies to 
over-come this problem to improve levels of compliance 
thereby reducing the risk of unnecessary seizures. In this 
study, frequency of non-compliance of antiepileptic drugs 
in epileptic patients was revealed in 23.56% while 
76.44% had no complaint of non-compliance. The 
findings of the present study regarding frequency of 
non-compliance are in agreement with Hauser et al. (5) 
WHO reported that 19% of the patients had 
non-compliance in the outpatient group.(5) The evidence 
indicates that non-compliance is still common in 
healthcare and no substantial change occurred despite 
the large number of studies attempting to address and 
highlight the problem. In addition, too few studies are 
being done systematically to quantify the impact of 
non-compliance on health and financial outcomes. The 
magnitude of the impact of non-compliance needs to be 
studied in future compliance research due to the potential 
tremendous implication of poor compliance on clinical 
and economic outcomes.
CONCLUSION
We concluded that the frequency of noncompliance of 
antiepileptic drugs among epileptic patients is higher. This 
condition is worsening for males since they showed a 
greater percentage of non-compliance as compared to 
females. This situation needs special attention of the 
physicians while managing epileptic patients.
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BACKGROUND
Upper motor neuron (UMN) injury can result from a large 
number of conditions which are quite common in the 
population. The conditions which lead to UMN lesions 
include cerebrovascular accidents, traumatic brain injury, 
Parkinson’s disease, multiple sclerosis and suprasacral 
spinal cord injury, etc. Detrusor overactivity (DO) is one of 
the deleterious consequences of many upper motor 
neuron lesions. DO is underdiagnosed and commonly 
untreated. The problem is further compounded by 
complications like vesicoureteric reflux, hydronephrosis, 
nephropathy, urinary tract infections, urolithiasis, chronic 
kidney disease and even malignancy.[1] This deteriorates 
the quality of life of the patient not only due to medical 
complications but also because of the ensuing depression 
and social stigmatization thus creating hindrance in early 
achievement of rehabilitation goals. At the same time, the 
complications put an extra burden on the healthcare 
system. This is the reason why treatment of bladder 
dysfunction is an important pillar in the management of 
upper motor neuron lesions. Bladder management in 
UMN lesions focuses on carefully diagnosing the 
underlying bladder disorder and its targeted treatment. 
The treatment of DO can be undertaken on clinical 
grounds but it is beneficial to quantify the defect on 
objective parameters like the urodynamic study because it 
helps in monitoring the response to treatment and in 
gathering data for future follow up. The aim of bladder 
management in DO is to improve the bladder capacity and 
decrease the detrusor contractions in order to enable 
clean intermittent catheterization (CIC) by the patient. 
This can be achieved by various modalities including 
pharmacotherapy as well as surgical options. 
Pharmacotherapy is the most commonly used first line 
treatment because of non-invasiveness, efficacy and ease 
of use. The drug options include anticholinergics/ 
antimuscarinics, tricyclics, intravesical instillation of 
capsaicin or lignocaine and botulinum injections to the 
detrusor muscle. Anti-muscarinic agents are the 
backbone of pharmacological treatment for DO.[2,3] These 
agents are used to abolish detrusor contractions in order 
to permit voiding by CIC. Antimuscarinics have been 
considered the gold standard of treatment for many 
decades but are well-known for their side effects 
presenting as dry mouth, constipation and tachycardia.  
Oxybutynin is the most commonly used drug in this class 
and can be used orally and/ or intravesically.[4] Tolterodine 
is another commonly used antimuscarinic agent and has 
lesser incidence of side effects than oxybutynin in usual 
doses.[5] Recently, many newer drugs with better 
tolerability have been added to the arsenal against DO.[6] 
In Pakistan, most patients are unable to afford the newer 
agents. The mainstay of treatment for DO remains either 
oxybutynin or tolterodine, out of which oxybutynin is the 
cheaper choice.[7] International studies have proved that 
both these drugs have a comparable efficacy in dealing 
with DO.[8,9,10] No study has been conducted in our 
indigenous population to address this issue so far, using 
objective and measurable outcomes like improvement in 
urodynamic parameters. This issue has been addressed in 
the present study which aims to gather reproducible data 
on the subject.
MATERIALS AND METHODS
It was a single blinded randomized controlled trial carried 
out at Armed Forces Institute of Rehabilitation Medicine, 
Rawalpindi from January 2015 to August 2015. We 
included individuals belonging to both genders fitting in 
the age group of 18-60 years with a diagnosis of DO as a 
result of upper motor neuron lesions. We had chosen the 
above mentioned age limit to lessen the influence of 
confounding factors in geriatric and pediatric population. 
Above 60 years, the females are likely to have stress 
incontinence and males are prone to develop lower 
urinary tract symptoms due to prostatic disease. Likewise, 
the urodynamic parameters in the pediatric population are 
different than adults. Patients having conditions other 
than DO that might have led to urinary incontinence or 
urgency e.g. urinary tract infection, prostatic hypertrophy 
or utero-vaginal prolapse were excluded from the study. 
Smokers and women who were pregnant or breast feeding 
their children were also placed in the exclusion group. 
After approval from the hospital ethics committee, 
prospective candidates for enrollment were evaluated 
thoroughly to meet the inclusion criteria. Patient’s 
informed consent for participation was taken after 
explaining the objectives and benefits of the study. The 
patients who were enrolled underwent baseline 
urodynamic studies using PICO SMART Urodynamics 
System (PICO SMART, Menfis Division, MEDICA S.p.A., 
Bologna, Italy) to quantify maximal detrusor pressure 
(MDP) and maximal cystometric capacity (MCC). MDP is 
the pressure created by bladder wall forces. It is a 
component of intravesical pressure and is calculated by 
subtracting abdominal pressure from intravesical 
pressure. It was measured in cm of H2O. MCC is the 
volume at which the patient feels that he/she can no 
longer delay micturition. It was measured in ml. The 
patients were consecutively divided into two study groups 
i.e. Group A and B. Group A was treated with oral 
tolterodine (Detrusitol, Pfizer Laboratories, Karachi, 
Pakistan) 2 mg twelve hourly [11] and group B received oral 
oxybutynin (Taivor, Raazee Therapeutics, Lahore, 
Pakistan) 3 mg eight hourly.[12] The urodynamic 
parameters assessed at baseline were repeated after four 
weeks. The data were endorsed for each patient in a 
written proforma. The data were analyzed with the help of 
statistical program Statistical Package for Social sciences 
(SPSS) version 19.0 (IBM Corp., Armonk, NY, USA). 
Descriptive statistics were calculated for both qualitative 
and quantitative variables. For qualitative variables like 
gender and primary diagnosis of UMN lesion, frequencies 
and percentages were calculated and for quantitative 
variables like age, MDP and MCC, means and standard 
deviations were calculated. Paired-samples t-test was 
applied to statistically analyze the effect of both 
therapeutic modalities in either study groups. The mean 
reduction in MCC and MDP between two groups were 
compared using independent-samples t-test. A p-value < 
0.05 was considered significant.
RESULTS
A total of 60 patients suffering from UMN pathology 
attributed to various clinical conditions, regardless of age 
and gender, were included in the study. Fifty patients 
(83.3%) were male and ten (16.7%) were female. Mean 
age of the patients was 43.9 ± 15 years with a range of 
13-72 years. The cause of upper motor neuron lesion was 
spinal cord injury in 56.7% (n=34)  of the patients 
followed by cerebrovascular accident (23.3%,n=14), 
Parkinson’s disease (5%,n=3), cerebral palsy (5%, n=3), 
spinal tuberculosis (5%,n=3), acquired brain injury 
(3.3%,n=2) and spinal cord tumors (1.7%, n=1) 
(Figure-1). Mean pre-treatment MCC was 199.1 ± 55.5 
ml, and the mean post-treatment MCC was 295.1 ± 59 
ml. Mean pretreatment MDP was 82.1 ± 10.2 cm of 
H2O, and the mean post-treatment value was 40.8 ± 
10.1 cm of H2O.
 
Figure-1: Figure showing relative percentages of different 
primary etiologies for upper motor neuron lesion in the sample
Twenty-six males and 4 females (n=30) were in group A. 
Rest of the 24 males and 6 females (n=30), were in 
group B. Group A had a mean pre-treatment MCC of 
188.3 ± 48.2 ml, and a mean post-treatment MCC of 
281.5 ± 49.1 ml. (Table-1) The mean pretreatment MDP 
was 83.6 ± 9.5 cm of H2O, and the mean 
post-treatment value was 40.9 ± 10.2 cm of H2O. Group 
B had a mean pre-treatment MCC of 209.8 ± 60.5 ml, 
and mean post-treatment MCC of 308.7 ± 65 ml. The 
mean pretreatment MDP was 80.7 ± 10.6 cm of H2O, 
and the mean post-treatment value was 40.7 ± 10.1 cm 
of H2O.(Table-1)
Each drug significantly reduced MCC and MDP in its group 
(p< 0.001, p< 0.001, p< 0.001 and p< 0.001 
respectively). The mean reduction in MCC produced by 
tolterodine (93.2 ± 18.6) was less than that produced by 
oxybutynin (98.9 ± 26.7) but did not satisfy the statistical 
tests for significance (p=0.179). Similarly, the mean 
reduction in MDP produced by tolterodine (42.7 ± 3.9) 
was more than that produced by oxybutynin (40 ± 10.6) 
but could not reach a statistically significant value (p= 
0.068).
DISCUSSION
DO is commonly seen in patients with UMN lesions as 
evidenced by various community and hospital based 
surveys. The complications relating to this disorder are 
also quite frequent in this population which can be 
averted to some extent by the use of appropriate 
modalities. For these patients the care of the bladder is an 
essential component of any rehabilitation program. In 
practice, balancing between efficacy and side effects is a 
challenge. Moreover, cost effectiveness is a major 
determinant in choosing the appropriate drugs especially 
in poor countries. A lot of studies have been conducted to 
determine the safety and efficacy of antimuscarinic 
agents that are the cornerstone of treatment in patients 
with both neurogenic and non-neurogenic DO. We also 
tried to find out the difference in efficacy of commonly 
available antimuscarinic agents available in Pakistan while 
targeting Pakistani population. We found that, though 
both tolterodine and oxybutynin were effective in reducing 
MDP and MCC, there was no significant difference in the 
magnitude of effect produced by both drugs. Madhuvrata 
P et al. embarked upon a study to compare the two drugs 
in question in our study. They concentrated on bladder 
leakage episodes in 24 hours and patients’ perception of 
improvement in quality of life. Their results were similar to 
ours in that both the drugs caused significant but 
comparable improvements in subjective parameters. [13] 
In a double blind, multicenter study carried out to 
compare relative effectiveness of tolterodine (4 mg daily), 
transdermal oxybutynin and placebo [14], no significant 
differences were seen in the outcome parameters 
between the two drugs. However, both were significantly 
more effective than placebo in reducing incontinence 
episodes (75% vs 50%) both P < 0.05 vs placebo. In the 
Overactive Bladder: Performance of Extended Release 
Agents (OPERA) trial, a comparison was made between 
extended release oxybutynin (OXY-ER, 10 mg) and 
tolterodine(TOL-ER, 4 mg). With both these drugs, 
comparable results were obtained regarding control of 
incontinence. However oxybutynin was found to had a 
greater impact on the total micturition frequency per week 
(28.4 vs 25.2; P = 0.003) as well as overall dry rate 
(23% vs 16.8%; P = 0.03).[15] Many studies have 
established a superiority of tolterodine over oxybutynin in 
side effects’ profile. This has led to more compliance with 
tolterodine therapy and fewer dropouts. The side effect 
profile was found to be much better especially with 
dryness of mouth and cognitive impairment. This is 
because tolterodine has been documented to have 8-fold 
less affinity to the muscarinic receptors at the parotid 
gland in radioligand binding.[16, 17, 18] We under took this 
study because of the high burden of this disorder in the 
outdoor and as well as the indoor in our Institute. We 
searched but did not find a single indigenous study on this 
topic using urodynamic parameters as the gauge to 
determine efficacy. Our study was carried out to try to 
address this issue. We, the physicians in the third world, 
more than our counterparts in the developed world, have 
to balance the efficacy of a drug against its cost. 
Oxybutynin is a relatively cheaper drug and therefore is 
more easily available to our patients. Based on the 
volume of literature in favor of comparable effectiveness 
of oxybutynin and tolterodine, we chose the null 
hypothesis to be the expected outcome on urodynamic 
parameters. As hypothesized, our results revealed no 
significant difference in the relative effectiveness of these 
two drugs. Therefore our study validates the results of 
previous studies as mentioned above. This has helped us 
to be more confident in prescribing this drug without 
feeling the guilt of withholding a potentially better drug 

















Tolterodine 188.3 ± 48.2 MCC of 281.5 ± 49.1 
93.2 ± 18.6,  
p < 0.001 
83.6 ± 9.5 40.9 ± 10.2 42.7 ± 3.9, p < 0.001 
Oxybutynin 209.8 ± 60.5 308.7 ± 65 
98.9 ± 26.7,  
p < 0.001 
80.7 ± 10.6 40.7 ± 10.1 
40 ± 10.6,  
p < 0.001 
*MCC: Maximalcystometric capacity
**MDP:Maximaldetrusor pressure
Table-1:Table showing comparison of the effect of oxybutynin and tolterodineonmaximal cystometric capacity and
maximaldetrusor pressure
*MCC: maximal cystometric capacity
**MDP: Maximal detrusor pressure
Table-1: Table showing comparison of the effect of 
oxybutynin and tolterodine on maximal cystometric capacity 
and maximal detrusor pressure
because of financial constraints. The study had a 
shortcoming. A long term follow up was required to 
determine the relative frequency of long term treatment 
failures and dropouts amongst the two groups which could 
not be carried out properly because of time limitation.
CONCLUSIONS
Both oxybutynin and tolterodine showed similar efficacy in 
the treatment of DO based on measurable urodynamic 
outcomes. The improvements in the urodynamic 
parameters were significant with both these drugs, so 
their regular use in appropriate patients is justified. Our 
study was the first of its kind in Pakistan. As mentioned 
earlier, the database available on DO is not of a very high 
quality, therefore there is a need to continue research on 
this subject to further elucidate the differences in 
response to treatment, if any, amongst the various causes 
of neurogenic bladder.
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INTRODUCTION
Epilepsy is a chronic condition in which non-compliance is 
considered to be a significant problem faced during clinical 
treatment. Poor compliance to treatment is one of many 
reasons for pharmacological treatment failure and seizure 
recurrence. Despite all the best intention and efforts on 
the part of the healthcare professionals, those outcomes 
might not be achievable if the patients are non-compliant. 
(1) The behavior of compliance depends on specific clinical 
situation, nature of the illness, and treatment program. 
The effect of recurrent epileptic seizure attacks on the 
patient is far reaching. Poor compliance may lead to status 
epilepticus, as well as unexpected, sudden death. (2) 
Recurrent convulsions can reduce the likelihood of 
eventually curing the disorder. With appropriate treatment 
and lifestyle changes, the majority of patients diagnosed 
with epilepsy will become seizure-free. Compliant 
behaviour can be defined as taking anti-epileptic drugs 
(AEDs) on time and without fail, not manipulating dosages, 
and following the doctor’s advice regarding daily activities. 
(2) Non-compliance is a significant problem in epilepsy 
management. As many as 30 to 50% of persons with 
epilepsy are non-compliant to the extent of interfering with 
their optimal treatment. (2) The effect of non-compliance is 
enormous and may lead to an increase in the number of 
seizures, medical costs and injury to themselves and 
others.(2) The frequency of non-compliance was 19% in the 
outpatient group as reported in one study. (3) Reasons for 
non-compliance are complex and multilayered. Patients 
can accidentally fail to adhere through forgetfulness, 
misunderstanding, or uncertainty about clinician’s 
recommendations, or intentionally due to their own 
expectations of treatment, side-effects, and lifestyle 
choice. (3) In India, a study relating to doctor-patient 
communication and compliance stated that compliance 
improved when patients were satisfied with the 
consultation process and were asked to recall the 
information. Multiple visits to the doctor enhanced 
communication, and thus compliant behaviour. (4) Most of 
studies have attempted either to identify predictors or to 
measure the incidence of non-compliance but there is not 
a validated scale for measuring epilepsy patient 
non-compliance to antiepileptic drugs. This is especially 
true for developing countries including Pakistan. The lack 
of these measurements provides difficulties to assess the 
impact of specific factors in compliance to treatment. 
Services Hospital is the regional hospital in the central 
Punjab and serves a huge population of the country. There 
is scarcity of published data reporting the prevalence of 
epileptic patients with noncompliance of antiepileptic 
drugs. In the present study, we have aimed to determine 
the prevalence of compliance and non-compliance of 
antiepileptic drugs in epileptic patients. 
MATERIALS AND METHODS
The present study was conducted in OPD (Outpatient 
Department) at Services Institute of Medical Sciences and 
Services Hospital, Lahore, Pakistan. This 6-month 
descriptive study was carried out in 2012 and included a 
total of 225 patients who were admitted with the primary 
diagnosis of Epilepsy. Male and female patients aged 
between 10 to 70 years, who had been diagnosed with 
epilepsy at least one year previously, were included. 
Patients having other co-morbidities were excludded from 
this study. The data-collection tools were a questionnaire 
and a structured interview. Patients who were not able to 
respond to an interview were also excluded. For each 
patient detail history was taken including demographic 
information (age, sex, address) and questionnaire was 
asked after taking informed consent by researcher herself. 
All patients were observed for anti-epilepsy drug 
compliance and non-compliance. Patients included in 
study, were treated free of cost. Participants gave written 
informed consent after the purpose of the study had been 
explained to them. The ethics committee of the hospital 
approved the study. 
Statistical Analyses
The descriptive statistical analysis included examinations 
of means, standard deviations, frequencies, ranges, and 
percentages. The statistical packages SPSS (Version 20) 
and MS Excel (MS Office 2010) were used. 
RESULTS
A total of 225 patients fulfilling the inclusion criteria were 
enrolled to measure the frequency of noncompliance of 
antiepileptic drugs in epileptic patients. Age distribution of 
the patients was done which showed that 29.78% 
(n=67) were between 10-30 years, 36% (n=81) 
between 41-55 years and 34.22% (n=77) were between 
56-70 years of age. Average age of the patients was 
46.87+5.23 years (Table 1). 
Table 1. Age distribution of patients included in the study.
Mean and SD: 46.87+5.23 (n= 225)
Gender distribution of the patients showed that 59.6% 
(n=134) were males and 40.4% (n=91) were females 
(Table 2). 
Table 2. Gender distribution of all patients included in this 
study.
Results regarding the frequency of epileptic patients with 
compliance and non-compliance of antiepileptic drugs 
have been shown in Figure 1. Figure shows that out of 
225 patients, 172 patients (76.4%) had compliance of 
antiepileptic drugs. Whereas 53 patients (23.6%) showed 
non-compliance to antiepileptic drugs (Figure 1).
 
Figure 1. Frequency of compliance and non-compliance 
of antiepileptic drugs among epileptic patients.
We also identified the gender distribution of epileptic 
patients with non-compliance of antiepileptic drugs. The 
results have been shown in Table 3 which shows that out 
of 53 cases of non-compliance, 33 cases (62.3%) were 
male and 20 cases (37.7%) were females (Table 3). This 
finding showed that incidence of non-compliance was 
more frequent in males as compared to females.
Table 3. Stratification for noncompliance of antiepileptic 




The sole treatment available for the majority of patients 
with epilepsy is antiepileptic drug (AED) therapy. Research 
has shown that missing or altering antiepileptic drug 
dosages can have adverse reactions, that is, increase the 
chance of seizure recurrence. For instance, Mattson et al. 
reported that over one quarter of seizures occurred at or 
before reports of inadequate medication levels. Failure to 
follow prescribed drug regimens is known to be fairly 
widespread amongst patients with epilepsy: research has 
shown that between 25 and 75% fail to adhere, in 
particular very young or very old patients, and teenagers. 
Given that failing to comply may increase the likelihood of 
hospital admission, there could be a potential savings if 
compliance could be improved. We planned this study to 
determine the most prevalent factors in Pakistan because 
demographic, psychosocial, economic factors, literacy 
rate is different. Non-compliance of antiepileptic drugs in 
epileptic patients leads to recurrent seizures, thus mental 
regression occurs (2); by knowing the frequency of 
non-compliance, we can adopt some strategies to 
over-come this problem to improve levels of compliance 
thereby reducing the risk of unnecessary seizures. In this 
study, frequency of non-compliance of antiepileptic drugs 
in epileptic patients was revealed in 23.56% while 
76.44% had no complaint of non-compliance. The 
findings of the present study regarding frequency of 
non-compliance are in agreement with Hauser et al. (5) 
WHO reported that 19% of the patients had 
non-compliance in the outpatient group.(5) The evidence 
indicates that non-compliance is still common in 
healthcare and no substantial change occurred despite 
the large number of studies attempting to address and 
highlight the problem. In addition, too few studies are 
being done systematically to quantify the impact of 
non-compliance on health and financial outcomes. The 
magnitude of the impact of non-compliance needs to be 
studied in future compliance research due to the potential 
tremendous implication of poor compliance on clinical 
and economic outcomes.
CONCLUSION
We concluded that the frequency of noncompliance of 
antiepileptic drugs among epileptic patients is higher. This 
condition is worsening for males since they showed a 
greater percentage of non-compliance as compared to 
females. This situation needs special attention of the 
physicians while managing epileptic patients.
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BACKGROUND
Upper motor neuron (UMN) injury can result from a large 
number of conditions which are quite common in the 
population. The conditions which lead to UMN lesions 
include cerebrovascular accidents, traumatic brain injury, 
Parkinson’s disease, multiple sclerosis and suprasacral 
spinal cord injury, etc. Detrusor overactivity (DO) is one of 
the deleterious consequences of many upper motor 
neuron lesions. DO is underdiagnosed and commonly 
untreated. The problem is further compounded by 
complications like vesicoureteric reflux, hydronephrosis, 
nephropathy, urinary tract infections, urolithiasis, chronic 
kidney disease and even malignancy.[1] This deteriorates 
the quality of life of the patient not only due to medical 
complications but also because of the ensuing depression 
and social stigmatization thus creating hindrance in early 
achievement of rehabilitation goals. At the same time, the 
complications put an extra burden on the healthcare 
system. This is the reason why treatment of bladder 
dysfunction is an important pillar in the management of 
upper motor neuron lesions. Bladder management in 
UMN lesions focuses on carefully diagnosing the 
underlying bladder disorder and its targeted treatment. 
The treatment of DO can be undertaken on clinical 
grounds but it is beneficial to quantify the defect on 
objective parameters like the urodynamic study because it 
helps in monitoring the response to treatment and in 
gathering data for future follow up. The aim of bladder 
management in DO is to improve the bladder capacity and 
decrease the detrusor contractions in order to enable 
clean intermittent catheterization (CIC) by the patient. 
This can be achieved by various modalities including 
pharmacotherapy as well as surgical options. 
Pharmacotherapy is the most commonly used first line 
treatment because of non-invasiveness, efficacy and ease 
of use. The drug options include anticholinergics/ 
antimuscarinics, tricyclics, intravesical instillation of 
capsaicin or lignocaine and botulinum injections to the 
detrusor muscle. Anti-muscarinic agents are the 
backbone of pharmacological treatment for DO.[2,3] These 
agents are used to abolish detrusor contractions in order 
to permit voiding by CIC. Antimuscarinics have been 
considered the gold standard of treatment for many 
decades but are well-known for their side effects 
presenting as dry mouth, constipation and tachycardia.  
Oxybutynin is the most commonly used drug in this class 
and can be used orally and/ or intravesically.[4] Tolterodine 
is another commonly used antimuscarinic agent and has 
lesser incidence of side effects than oxybutynin in usual 
doses.[5] Recently, many newer drugs with better 
tolerability have been added to the arsenal against DO.[6] 
In Pakistan, most patients are unable to afford the newer 
agents. The mainstay of treatment for DO remains either 
oxybutynin or tolterodine, out of which oxybutynin is the 
cheaper choice.[7] International studies have proved that 
both these drugs have a comparable efficacy in dealing 
with DO.[8,9,10] No study has been conducted in our 
indigenous population to address this issue so far, using 
objective and measurable outcomes like improvement in 
urodynamic parameters. This issue has been addressed in 
the present study which aims to gather reproducible data 
on the subject.
MATERIALS AND METHODS
It was a single blinded randomized controlled trial carried 
out at Armed Forces Institute of Rehabilitation Medicine, 
Rawalpindi from January 2015 to August 2015. We 
included individuals belonging to both genders fitting in 
the age group of 18-60 years with a diagnosis of DO as a 
result of upper motor neuron lesions. We had chosen the 
above mentioned age limit to lessen the influence of 
confounding factors in geriatric and pediatric population. 
Above 60 years, the females are likely to have stress 
incontinence and males are prone to develop lower 
urinary tract symptoms due to prostatic disease. Likewise, 
the urodynamic parameters in the pediatric population are 
different than adults. Patients having conditions other 
than DO that might have led to urinary incontinence or 
urgency e.g. urinary tract infection, prostatic hypertrophy 
or utero-vaginal prolapse were excluded from the study. 
Smokers and women who were pregnant or breast feeding 
their children were also placed in the exclusion group. 
After approval from the hospital ethics committee, 
prospective candidates for enrollment were evaluated 
thoroughly to meet the inclusion criteria. Patient’s 
informed consent for participation was taken after 
explaining the objectives and benefits of the study. The 
patients who were enrolled underwent baseline 
urodynamic studies using PICO SMART Urodynamics 
System (PICO SMART, Menfis Division, MEDICA S.p.A., 
Bologna, Italy) to quantify maximal detrusor pressure 
(MDP) and maximal cystometric capacity (MCC). MDP is 
the pressure created by bladder wall forces. It is a 
component of intravesical pressure and is calculated by 
subtracting abdominal pressure from intravesical 
pressure. It was measured in cm of H2O. MCC is the 
volume at which the patient feels that he/she can no 
longer delay micturition. It was measured in ml. The 
patients were consecutively divided into two study groups 
i.e. Group A and B. Group A was treated with oral 
tolterodine (Detrusitol, Pfizer Laboratories, Karachi, 
Pakistan) 2 mg twelve hourly [11] and group B received oral 
oxybutynin (Taivor, Raazee Therapeutics, Lahore, 
Pakistan) 3 mg eight hourly.[12] The urodynamic 
parameters assessed at baseline were repeated after four 
weeks. The data were endorsed for each patient in a 
written proforma. The data were analyzed with the help of 
statistical program Statistical Package for Social sciences 
(SPSS) version 19.0 (IBM Corp., Armonk, NY, USA). 
Descriptive statistics were calculated for both qualitative 
and quantitative variables. For qualitative variables like 
gender and primary diagnosis of UMN lesion, frequencies 
and percentages were calculated and for quantitative 
variables like age, MDP and MCC, means and standard 
deviations were calculated. Paired-samples t-test was 
applied to statistically analyze the effect of both 
therapeutic modalities in either study groups. The mean 
reduction in MCC and MDP between two groups were 
compared using independent-samples t-test. A p-value < 
0.05 was considered significant.
RESULTS
A total of 60 patients suffering from UMN pathology 
attributed to various clinical conditions, regardless of age 
and gender, were included in the study. Fifty patients 
(83.3%) were male and ten (16.7%) were female. Mean 
age of the patients was 43.9 ± 15 years with a range of 
13-72 years. The cause of upper motor neuron lesion was 
spinal cord injury in 56.7% (n=34)  of the patients 
followed by cerebrovascular accident (23.3%,n=14), 
Parkinson’s disease (5%,n=3), cerebral palsy (5%, n=3), 
spinal tuberculosis (5%,n=3), acquired brain injury 
(3.3%,n=2) and spinal cord tumors (1.7%, n=1) 
(Figure-1). Mean pre-treatment MCC was 199.1 ± 55.5 
ml, and the mean post-treatment MCC was 295.1 ± 59 
ml. Mean pretreatment MDP was 82.1 ± 10.2 cm of 
H2O, and the mean post-treatment value was 40.8 ± 
10.1 cm of H2O.
 
Figure-1: Figure showing relative percentages of different 
primary etiologies for upper motor neuron lesion in the sample
Twenty-six males and 4 females (n=30) were in group A. 
Rest of the 24 males and 6 females (n=30), were in 
group B. Group A had a mean pre-treatment MCC of 
188.3 ± 48.2 ml, and a mean post-treatment MCC of 
281.5 ± 49.1 ml. (Table-1) The mean pretreatment MDP 
was 83.6 ± 9.5 cm of H2O, and the mean 
post-treatment value was 40.9 ± 10.2 cm of H2O. Group 
B had a mean pre-treatment MCC of 209.8 ± 60.5 ml, 
and mean post-treatment MCC of 308.7 ± 65 ml. The 
mean pretreatment MDP was 80.7 ± 10.6 cm of H2O, 
and the mean post-treatment value was 40.7 ± 10.1 cm 
of H2O.(Table-1)
Each drug significantly reduced MCC and MDP in its group 
(p< 0.001, p< 0.001, p< 0.001 and p< 0.001 
respectively). The mean reduction in MCC produced by 
tolterodine (93.2 ± 18.6) was less than that produced by 
oxybutynin (98.9 ± 26.7) but did not satisfy the statistical 
tests for significance (p=0.179). Similarly, the mean 
reduction in MDP produced by tolterodine (42.7 ± 3.9) 
was more than that produced by oxybutynin (40 ± 10.6) 
but could not reach a statistically significant value (p= 
0.068).
DISCUSSION
DO is commonly seen in patients with UMN lesions as 
evidenced by various community and hospital based 
surveys. The complications relating to this disorder are 
also quite frequent in this population which can be 
averted to some extent by the use of appropriate 
modalities. For these patients the care of the bladder is an 
essential component of any rehabilitation program. In 
practice, balancing between efficacy and side effects is a 
challenge. Moreover, cost effectiveness is a major 
determinant in choosing the appropriate drugs especially 
in poor countries. A lot of studies have been conducted to 
determine the safety and efficacy of antimuscarinic 
agents that are the cornerstone of treatment in patients 
with both neurogenic and non-neurogenic DO. We also 
tried to find out the difference in efficacy of commonly 
available antimuscarinic agents available in Pakistan while 
targeting Pakistani population. We found that, though 
both tolterodine and oxybutynin were effective in reducing 
MDP and MCC, there was no significant difference in the 
magnitude of effect produced by both drugs. Madhuvrata 
P et al. embarked upon a study to compare the two drugs 
in question in our study. They concentrated on bladder 
leakage episodes in 24 hours and patients’ perception of 
improvement in quality of life. Their results were similar to 
ours in that both the drugs caused significant but 
comparable improvements in subjective parameters. [13] 
In a double blind, multicenter study carried out to 
compare relative effectiveness of tolterodine (4 mg daily), 
transdermal oxybutynin and placebo [14], no significant 
differences were seen in the outcome parameters 
between the two drugs. However, both were significantly 
more effective than placebo in reducing incontinence 
episodes (75% vs 50%) both P < 0.05 vs placebo. In the 
Overactive Bladder: Performance of Extended Release 
Agents (OPERA) trial, a comparison was made between 
extended release oxybutynin (OXY-ER, 10 mg) and 
tolterodine(TOL-ER, 4 mg). With both these drugs, 
comparable results were obtained regarding control of 
incontinence. However oxybutynin was found to had a 
greater impact on the total micturition frequency per week 
(28.4 vs 25.2; P = 0.003) as well as overall dry rate 
(23% vs 16.8%; P = 0.03).[15] Many studies have 
established a superiority of tolterodine over oxybutynin in 
side effects’ profile. This has led to more compliance with 
tolterodine therapy and fewer dropouts. The side effect 
profile was found to be much better especially with 
dryness of mouth and cognitive impairment. This is 
because tolterodine has been documented to have 8-fold 
less affinity to the muscarinic receptors at the parotid 
gland in radioligand binding.[16, 17, 18] We under took this 
study because of the high burden of this disorder in the 
outdoor and as well as the indoor in our Institute. We 
searched but did not find a single indigenous study on this 
topic using urodynamic parameters as the gauge to 
determine efficacy. Our study was carried out to try to 
address this issue. We, the physicians in the third world, 
more than our counterparts in the developed world, have 
to balance the efficacy of a drug against its cost. 
Oxybutynin is a relatively cheaper drug and therefore is 
more easily available to our patients. Based on the 
volume of literature in favor of comparable effectiveness 
of oxybutynin and tolterodine, we chose the null 
hypothesis to be the expected outcome on urodynamic 
parameters. As hypothesized, our results revealed no 
significant difference in the relative effectiveness of these 
two drugs. Therefore our study validates the results of 
previous studies as mentioned above. This has helped us 
to be more confident in prescribing this drug without 
feeling the guilt of withholding a potentially better drug 
because of financial constraints. The study had a 
shortcoming. A long term follow up was required to 
determine the relative frequency of long term treatment 
failures and dropouts amongst the two groups which could 
not be carried out properly because of time limitation.
CONCLUSIONS
Both oxybutynin and tolterodine showed similar efficacy in 
the treatment of DO based on measurable urodynamic 
outcomes. The improvements in the urodynamic 
parameters were significant with both these drugs, so 
their regular use in appropriate patients is justified. Our 
study was the first of its kind in Pakistan. As mentioned 
earlier, the database available on DO is not of a very high 
quality, therefore there is a need to continue research on 
this subject to further elucidate the differences in 
response to treatment, if any, amongst the various causes 
of neurogenic bladder.
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INTRODUCTION
Epilepsy is a chronic condition in which non-compliance is 
considered to be a significant problem faced during clinical 
treatment. Poor compliance to treatment is one of many 
reasons for pharmacological treatment failure and seizure 
recurrence. Despite all the best intention and efforts on 
the part of the healthcare professionals, those outcomes 
might not be achievable if the patients are non-compliant. 
(1) The behavior of compliance depends on specific clinical 
situation, nature of the illness, and treatment program. 
The effect of recurrent epileptic seizure attacks on the 
patient is far reaching. Poor compliance may lead to status 
epilepticus, as well as unexpected, sudden death. (2) 
Recurrent convulsions can reduce the likelihood of 
eventually curing the disorder. With appropriate treatment 
and lifestyle changes, the majority of patients diagnosed 
with epilepsy will become seizure-free. Compliant 
behaviour can be defined as taking anti-epileptic drugs 
(AEDs) on time and without fail, not manipulating dosages, 
and following the doctor’s advice regarding daily activities. 
(2) Non-compliance is a significant problem in epilepsy 
management. As many as 30 to 50% of persons with 
epilepsy are non-compliant to the extent of interfering with 
their optimal treatment. (2) The effect of non-compliance is 
enormous and may lead to an increase in the number of 
seizures, medical costs and injury to themselves and 
others.(2) The frequency of non-compliance was 19% in the 
outpatient group as reported in one study. (3) Reasons for 
non-compliance are complex and multilayered. Patients 
can accidentally fail to adhere through forgetfulness, 
misunderstanding, or uncertainty about clinician’s 
recommendations, or intentionally due to their own 
expectations of treatment, side-effects, and lifestyle 
choice. (3) In India, a study relating to doctor-patient 
communication and compliance stated that compliance 
improved when patients were satisfied with the 
consultation process and were asked to recall the 
information. Multiple visits to the doctor enhanced 
communication, and thus compliant behaviour. (4) Most of 
studies have attempted either to identify predictors or to 
measure the incidence of non-compliance but there is not 
a validated scale for measuring epilepsy patient 
non-compliance to antiepileptic drugs. This is especially 
true for developing countries including Pakistan. The lack 
of these measurements provides difficulties to assess the 
impact of specific factors in compliance to treatment. 
Services Hospital is the regional hospital in the central 
Punjab and serves a huge population of the country. There 
is scarcity of published data reporting the prevalence of 
epileptic patients with noncompliance of antiepileptic 
drugs. In the present study, we have aimed to determine 
the prevalence of compliance and non-compliance of 
antiepileptic drugs in epileptic patients. 
MATERIALS AND METHODS
The present study was conducted in OPD (Outpatient 
Department) at Services Institute of Medical Sciences and 
Services Hospital, Lahore, Pakistan. This 6-month 
descriptive study was carried out in 2012 and included a 
total of 225 patients who were admitted with the primary 
diagnosis of Epilepsy. Male and female patients aged 
between 10 to 70 years, who had been diagnosed with 
epilepsy at least one year previously, were included. 
Patients having other co-morbidities were excludded from 
this study. The data-collection tools were a questionnaire 
and a structured interview. Patients who were not able to 
respond to an interview were also excluded. For each 
patient detail history was taken including demographic 
information (age, sex, address) and questionnaire was 
asked after taking informed consent by researcher herself. 
All patients were observed for anti-epilepsy drug 
compliance and non-compliance. Patients included in 
study, were treated free of cost. Participants gave written 
informed consent after the purpose of the study had been 
explained to them. The ethics committee of the hospital 
approved the study. 
Statistical Analyses
The descriptive statistical analysis included examinations 
of means, standard deviations, frequencies, ranges, and 
percentages. The statistical packages SPSS (Version 20) 
and MS Excel (MS Office 2010) were used. 
RESULTS
A total of 225 patients fulfilling the inclusion criteria were 
enrolled to measure the frequency of noncompliance of 
antiepileptic drugs in epileptic patients. Age distribution of 
the patients was done which showed that 29.78% 
(n=67) were between 10-30 years, 36% (n=81) 
between 41-55 years and 34.22% (n=77) were between 
56-70 years of age. Average age of the patients was 
46.87+5.23 years (Table 1). 
Table 1. Age distribution of patients included in the study.
Mean and SD: 46.87+5.23 (n= 225)
Gender distribution of the patients showed that 59.6% 
(n=134) were males and 40.4% (n=91) were females 
(Table 2). 
Table 2. Gender distribution of all patients included in this 
study.
Results regarding the frequency of epileptic patients with 
compliance and non-compliance of antiepileptic drugs 
have been shown in Figure 1. Figure shows that out of 
225 patients, 172 patients (76.4%) had compliance of 
antiepileptic drugs. Whereas 53 patients (23.6%) showed 
non-compliance to antiepileptic drugs (Figure 1).
 
Figure 1. Frequency of compliance and non-compliance 
of antiepileptic drugs among epileptic patients.
We also identified the gender distribution of epileptic 
patients with non-compliance of antiepileptic drugs. The 
results have been shown in Table 3 which shows that out 
of 53 cases of non-compliance, 33 cases (62.3%) were 
male and 20 cases (37.7%) were females (Table 3). This 
finding showed that incidence of non-compliance was 
more frequent in males as compared to females.
Table 3. Stratification for noncompliance of antiepileptic 




The sole treatment available for the majority of patients 
with epilepsy is antiepileptic drug (AED) therapy. Research 
has shown that missing or altering antiepileptic drug 
dosages can have adverse reactions, that is, increase the 
chance of seizure recurrence. For instance, Mattson et al. 
reported that over one quarter of seizures occurred at or 
before reports of inadequate medication levels. Failure to 
follow prescribed drug regimens is known to be fairly 
widespread amongst patients with epilepsy: research has 
shown that between 25 and 75% fail to adhere, in 
particular very young or very old patients, and teenagers. 
Given that failing to comply may increase the likelihood of 
hospital admission, there could be a potential savings if 
compliance could be improved. We planned this study to 
determine the most prevalent factors in Pakistan because 
demographic, psychosocial, economic factors, literacy 
rate is different. Non-compliance of antiepileptic drugs in 
epileptic patients leads to recurrent seizures, thus mental 
regression occurs (2); by knowing the frequency of 
non-compliance, we can adopt some strategies to 
over-come this problem to improve levels of compliance 
thereby reducing the risk of unnecessary seizures. In this 
study, frequency of non-compliance of antiepileptic drugs 
in epileptic patients was revealed in 23.56% while 
76.44% had no complaint of non-compliance. The 
findings of the present study regarding frequency of 
non-compliance are in agreement with Hauser et al. (5) 
WHO reported that 19% of the patients had 
non-compliance in the outpatient group.(5) The evidence 
indicates that non-compliance is still common in 
healthcare and no substantial change occurred despite 
the large number of studies attempting to address and 
highlight the problem. In addition, too few studies are 
being done systematically to quantify the impact of 
non-compliance on health and financial outcomes. The 
magnitude of the impact of non-compliance needs to be 
studied in future compliance research due to the potential 
tremendous implication of poor compliance on clinical 
and economic outcomes.
CONCLUSION
We concluded that the frequency of noncompliance of 
antiepileptic drugs among epileptic patients is higher. This 
condition is worsening for males since they showed a 
greater percentage of non-compliance as compared to 
females. This situation needs special attention of the 
physicians while managing epileptic patients.
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